---
title: "Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/600196.SH.md"
symbol: "600196.SH"
name: "Shanghai Fosun Pharmaceutical (Group) Co.,Ltd."
industry: "Pharmaceuticals"
---

# Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | CN Market |
| Website | [www.fosunpharma.com](https://www.fosunpharma.com) |

## Company Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous syste...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 72 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -4.96% |  |
| Net Profit YoY | 55.36% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.48 |  |
| Dividend Ratio | 1.19% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 70.95B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 39.55B |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.89% | C |
| Profit Margin | 8.30% | B |
| Gross Margin | 48.56% | B |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -4.96% | D |
| Net Profit YoY | 55.36% | B |
| Total Assets YoY | 2.48% | C |
| Net Assets YoY | 2.73% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1204.82% | B |
| OCF YoY | -4.96% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.34 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 48.52% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.89%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "8.30%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "48.56%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-4.96%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "55.36%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.48%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.73%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1204.82%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-4.96%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "48.52%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Allist (SH.688578) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A |
| 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B |
| 05 | Salubris (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 21.62 | 44/222 | 24.86 | 23.19 | 22.04 |
| PB | 1.48 | 31/222 | 1.59 | 1.49 | 1.40 |
| PS (TTM) | 1.79 | 29/222 | 1.91 | 1.80 | 1.60 |
| Dividend Yield | 1.19% | 93/222 | 1.16% | 1.11% | 1.06% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T16:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 50% |
| Overweight | 2 | 25% |
| Hold | 2 | 25% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 26.57 |
| Highest Target | 46.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/600196.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/600196.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/600196.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.